Order results by:
| Issue | Title | |
| Vol 13, No 4 (2021) | Toll-like receptors as a part of osteoarthritis pathophysiology: anti-inflammatory, analgesic and neuroprotective effects | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova, A. M. Lila, L. I. Alekseeva, E. A. Taskina | ||
| "... Toll-like receptors (TLRs) act as receptors for bacterial lipopolysaccharides (LPS ..." | ||
| Vol 15, No 1 (2023) | Chondroprotectors as modulators of neuroinflammation | Abstract similar documents |
| I. Y. Torshin, O. A. Gromova, A. G. Nazarenko | ||
| "... and differentiation of neurons; 3) inhibition of Toll-like receptors; 4) antioxidant and neuroprotective properties ..." | ||
| Vol 13, No 1 (2021) | Systematic analysis of molecular biological mechanisms for supporting connective tissue metabolism with chondroitin sulfate | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova, G. I. Nechaeva, I. A. Reier, N. V. Zagorodniy | ||
| "... , Toll-like receptors, and the NF-κB cascade through exposure to the CD44 receptor). Conclusion ..." | ||
| Vol 2, No 2 (2010) | Symptom modifiers in therapy for ankylosing spondylitis | Abstract similar documents |
| V. V. Badokin | ||
| Vol 13, No 3 (2021) | Pathogenesis, evaluation and pathogenetic therapy of diabetic polyneuropathy | Abstract similar documents |
| I. A. Strokov, V. V. Oganov | ||
| "... жирорастворимый антиоксидант. Симптом-модифицирующий эффект АЛК доказан в многочисленных рандомизированных ..." | ||
| Vol 4, No 2 (2012) | Artra is a model of combination symptom-modifying therapy for osteoarthrosis and intervertebral osteochondrosis | Abstract similar documents |
| V V Badokin | ||
| "... Препарат артра — модель комбинированной симптом-модифицирующей терапии остеоартроза и ..." | ||
| Vol 10, No 2 (2018) | Molecular mechanisms of action of glucosamine sulfate in the treatment of degenerative-dystrophic diseases of the joints and spine: results of proteomic analysis | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, A. M. Lila, A. N. Gromov | ||
| "... and discussion. GS interacts with the receptors CD44, TLR4, and ICAM1 on the surface of chondrocytes, inhibits ..." | ||
| Vol 6, No 3 (2014) | Current therapy for Parkinson's disease | Abstract similar documents |
| A. V. Obukhova | ||
| "... in the nigrostriatal system. Levodopa preparations and dopamine receptor agonists (DRAs) that are prescribed ..." | ||
| Vol 13, No 3 (2021) | Chondroitin sulfate in osteoarthritis treatment in patients with comorbid cardiovascular diseases: hypertension, atherosclerosis, coronary heart disease | Abstract similar documents |
| O. A. Shavlovskaya, I. A. Bokova, I. V. Sarvilina, N. I. Shavlovskiy, Yu. D. Yukhnovskaya | ||
| "... противовоспалительными препаратами. К таким ЛП относятся структурно-модифицирующие средства (SYSADOA), представителем ..." | ||
| Vol 12, No 5 (2020) | NMDA receptor antagonists in the treatment of neurological diseases | Abstract similar documents |
| I. S. Preobrazhenskaya | ||
| "... The paper reviews clinical trials evaluating the efficacy of N-methyl-D-aspartate (NMDA) receptor ..." | ||
| Vol 4, No 2 (2012) | Sigma receptors: their role in the treatment of affective disorders | similar documents |
| V E Medvedev | ||
| Vol 12, No 4 (2020) | The use of cannabinoids in epilepsy as an example: medical, social, and legal aspects | Abstract similar documents |
| R. G. Akzhigitov, K. I. Pochigayeva, F. K. Rider, A. M. Teplyshova, S. I. Dedayev, I. A. Shpak, E. V. Pashnin, A. B. Gekht | ||
| Vol 16 (2024): (Suppl. 2) | Global transcriptome profiling of blood mononuclear cells from individuals with radiologically isolated syndrome reveals abnormalities characteristic of the rapid manifestation of multiple sclerosis symptoms | Abstract similar documents |
| M. S. Kozin, A. R. Kabaeva, M. A. Omarova, A. N. Boyko, O. O. Favorova, O. G. Kulakova | ||
| "... by components of the Toll-like receptor signaling pathway. Conclusion. The transcriptome profiles of blood ..." | ||
| Vol 6, No 2S (2014): Special issue "Stroke" | NMDA receptor antagonists in the treatment of patients with vascular cognitive imprairments | Abstract similar documents |
| I.S. Preobrazhenskaya | ||
| "... The paper discusses the possibilities of using the NMDA receptor antagonist memantine in patients ..." | ||
| Vol 3, No 4 (2011) | Parkinson's disease fatigability and its correction with the dopamine receptor agonist pramipexole | Abstract similar documents |
| M. R. Nodel | ||
| "... ; to evaluate changes in the manifestations of fatigability during therapy with the dopamine receptor agonist ..." | ||
| Vol 4, No 2 (2012) | Capacities of the dopamine receptor agonist pramipexole in the treatment of patients with Parkinson’s disease | Abstract similar documents |
| S N Illarioshkin | ||
| "... receptor agonists (DRA) remains the leading pharmacotherapeutic strategy for Parkinson’s disease (PD ..." | ||
| Vol 12, No 2 (2020) | The history of mianserin and mirtazapine: study of their neurochemical activity and determination of their position in the classification of antidepressants | Abstract similar documents |
| D. S. Danilov, Yu. G. Tyulpin, V. D. Morozova | ||
| "... receptor and serotonin 5-HT2 receptor blockers». ..." | ||
| Vol 10, No 2 (2018) | Current management tactics for patients with dementia | Abstract similar documents |
| A. V. Medvedeva, O. V. Kosivtsova, K. A. Makhinov | ||
| "... inhibitors and N-methyl-D-aspartate (NMDA) glutamate receptor antagonists. Atypical neuroleptics are employed ..." | ||
| Vol 4, No 1 (2012) | Sustained-release pramipexole in the treatment of Parkinson’s disease | Abstract similar documents |
| Natalia Vladimirovna Fedorova | ||
| "... Dopamine (DA) receptor agonists ensure stimulation of DA receptors in the brain, by compensating ..." | ||
| Vol 2, No 3 (2010) | Treatment of parkinson's disease at a young age | Abstract similar documents |
| D. V. Artemyev | ||
| "... . Emphasis is laid on the key role of non-ergoline dopamine receptor agonists in the treatment of patients ..." | ||
| Vol 4, No 3 (2012) | Clinical experience with requip modutab | Abstract similar documents |
| Denis Valeryevich Zakharov, V A Mikhailov | ||
| "... The efficacy of dopamine receptor agonists (DRAs) is determined by a number of advantages. DRAs ..." | ||
| Vol 15, No 3 (2023) | Parkinson’s disease. Focus on early stages | Abstract similar documents |
| E. A. Katunina, Z. A. Zalyalova, D. V. Pokhabov, M. Z. Ivanova, A. M. Semenova | ||
| "... of age are recommended to start therapy with levodopa; younger patients – with dopamine receptor agonists ..." | ||
| Vol 17, No 3 (2025) | Parkinson's disease and migraine | Abstract similar documents |
| Z. A. Zalyalova, E. A. Katunina, D. V. Pokhabov | ||
| Vol 12, No 3 (2020) | Memantine: procognitive and antinegative effects in mental illness (a literature review) | Abstract similar documents |
| D. V. Romanov, P. G. Yuzbashyan | ||
| Vol 5, No 3 (2013) | The efficacy of the dopamine agonist Rotigotine in the treatment of Parkinson's disease | Abstract similar documents |
| Marina Romanovna Nodel | ||
| "... Rotigotine is a new, non-ergot dopamine receptor agonist (DRA) formulated as a transdermal drug ..." | ||
| Vol 13, No 3 (2021) | Profile and frequency of antiparkinsonian drugs adverse reactions: a systematic review and meta-analysis | Abstract similar documents |
| A. A. Tappakhov, T. E. Popova, A. I. Vasilev, T. G. Govorova, Yu. I. Khabarova, K. A. Timofeeva, N. A. Schnaider | ||
| "... number of ADRs among dopamine receptor agonists. Dizziness was more common with pramipexole ..." | ||
| Vol 14, No 2 (2022) | New potential biomarkers of Alzheimer's disease: markers of endothelial dysfunction and neuroinflammation. | Abstract similar documents |
| A. K. Minochkin, V. Yu. Lobzin, N. N. Suchentseva, O. S. Popov, S. V. Apalko, S. G. Sherbak | ||
| "... with the dementia stage in AD, and the interleukin-1 receptor antagonist (IL-1RA) levels, on the contrary ..." | ||
| Vol 4, No 1 (2012) | Association of the dopamine receptor (DRD4, DAT) gene polymorphisms with vital exhaustion in an open population among 25—64-year-old men (Novosibirsk): Epidemiological study according to the WHO MONICA-psychosocial program | Abstract similar documents |
| Valery Vasilyevich Gafarov, M I Voyevoda, E A Gromova, V N Maksimov, A V Gafarova, I V Gagulin, N S Yudin, T M Mishakova | ||
| "... of Medical Sciences (Novosibirsk). Results. The genotype containing allele 7 in the dopamine receptor subtype ..." | ||
| Vol 10, No 4 (2018) | Cognitive and motor training for patients with moderate cognitive impairment and mild dementia | Abstract similar documents |
| A. A. Naumenko, I. S. Preobrazhenskaya | ||
| Vol 8, No 2 (2016) | Alzheimer's disease under the mask of stroke | Abstract similar documents |
| A. A. Naumenko, N. V. Vakhnina | ||
| "... and vascular CIs are acetylcholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists ..." | ||
| Vol 8, No 4 (2016) | ALZHEIMER’S DISEASE: DIAGNOSIS AND TREATMENT | Abstract similar documents |
| A. A. Naumenko, D. O. Gromova, N. V. Trofimova, I. S. Preobrazhenskaya | ||
| Vol 13, No 2 (2021) | Female infertility as a factor of emotional disorder: the importance of psychotherapy in the treatment of infertility | Abstract similar documents |
| M. S. Golyshkina, M. N. Gevorgyan, V. N. Nikolenko, M. V. Oganesyan, P. A. Pavlyuk, N. A. Rizaeva, A. L. Unanyan | ||
| "... to have children and long-term treatment turns into a psychological problem. An Emotional toll leads ..." | ||
| Vol 16, No 5 (2024) | Resolution of the Expert Council on the problem of early diagnosis of Alzheimer's disease | Abstract similar documents |
| A. N. Bogolepova, E. E. Vasenina, N. V. Vakhnina, S. V. Vorobyеv, S. I. Gavrilova, А. Yu. Emelin, V. V. Zakharov, S. N. Illarioshkin, O. V. Kosivtsova, G. P. Kostyuk, O. S. Levin, E. A. Mkhitaryan, V. А. Parfenov, O. N. Tkacheva, Yu. A. Shpilyukova | ||
| "... эффективность как существующей, так и разрабатываемой (болезнь-модифицирующей) терапии БА максимальна именно на ..." | ||
| Vol 10, No 4 (2018) | Approaches to therapy for depressions in neurology: prospects for the use of agomelatine | Abstract similar documents |
| D. V. Romanov, B. A. Volel, D. S. Petelin | ||
| "... in neurological practice. The drug has a unique receptor profile, being a melatonin receptor type 1 and 2 agonist ..." | ||
| Vol 11, No 3S (2019): Спецвыпуск: когнитивные нарушения, цереброваскулярные заболевания | Non-drug therapies for cognitive impairment | Abstract similar documents |
| I. S. Preobrazhenskaya, D. Fantalis, S. A. Abdyshova, A. A. Kindarova | ||
| Vol 14, No 6 (2022) | Recombinant botulinum toxin as a new stage in the development of botulinum toxin therapy. Possibilities and perspectives of use in neurological practice | Abstract similar documents |
| R. K. Shikhkerimov, E. V. Istomina | ||
| "... -sensitive factor [NSF] Attachment Protein Receptor), as a result of which the release of acetylcholine ..." | ||
| Vol 14, No 6 (2022) | Gerstmann–Sträussler–Scheinker syndrome with early-onset spinocerebellar ataxia phenotype | Abstract similar documents |
| E. P. Nuzhnyi, N. Y. Abramycheva, E. Y. Fedotova, S. N. Illarioshkin | ||
| "... магнитно-резонансной томографии головного мозга. Обсуждается возможная модифицирующая роль полиморфизма в ..." | ||
| Vol 15, No 2 (2023) | New pharmaconutraceutical Chondroguard®TRIO for the prevention of musculoskeletal diseases and nutritional support for patients with osteoarthritis and nonspecific back pain: an assessment of clinical options. Resolution of the Multidisciplinary Expert Council | Abstract similar documents |
| Al. B. Danilov, A. M. Lila, Yo. N. Majidova, O. A. Gromova, O. N. Tkacheva, I. V. Sarvilina, A. Yu. Kochish, A. G. Nazarenko, N. V. Zagorodniy, T. B. Minasov, L. I. Alekseeva, E. A. Taskina, Yu. V. Kotovskaya, E. N. Dudinskaya, A. V. Rozanov, E. Yu. Solovieva, O. A. Shavlovskaya, M. N. Sharov, P. R. Kamchatnov, A. P. Rachin, E. R. Barantsevich, D. A. Iskra, E. Z. Yakupov, F. I. Devlikamova, A. E. Barulin, M. V. Nesterova, T. G. Sakovets, A. N. Barinov, I. N. Dolgova, N. V. Zabolotskikh, E. V. Zonova, L. A. Shchepankevich, V. A. Parfenov, A. T. Dzhurabekova, S. Z. Khakimova | ||
| "... , доказательную базу эффективности и безопасности применения препаратов, модифицирующих течение ОА (Disease ..." | ||
| Vol 9, No 2 (2017) | Chemoreactomic analysis of thiamine disulfide, thiamine hydrochloride, and benfotiamine molecules | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, L. V. Stakhovskaya, L. E. Fedotova | ||
| "... that thiamine disulfide can inhibit the molecular receptors involved in blood pressure regulation: adrenoceptors ..." | ||
| Vol 13, No 4 (2021) | Treatment of antipsychotic-induced parkinsonism in schizophrenic patients | Abstract similar documents |
| E. E. Vaiman, N. A. Shnayder, N. G. Neznanov, R. F. Nasyrova | ||
| "... anticholinergic drugs; NMDA receptor antagonists; dopamine receptor agonists; selective inhibitors of monoamine ..." | ||
| Vol 16, No 4 (2024) | Agomelatine: pharmacological profile, possible application, advantages | Abstract similar documents |
| V. E. Medvedev, O. V. Kotova, A. V. Palin, O. V. Mikheeva, E. S. Akarachkova | ||
| "... the properties of a dual 5-HT2С receptor antagonist as well as the properties of a melatonin MT1 and MT2 receptor ..." | ||
| Vol 16, No 5 (2024) | Gidazepam – daytime tranquilizer for the treatment of anxiety | Abstract similar documents |
| Yu. E. Azimova, D. S. Petelin | ||
| "... : lower affinity to GABAА-receptors than classical benzodiazepines, partial agonism and modulation ..." | ||
| Vol 17, No 3 (2025) | Switching from ocrelizumab to ofatumumab: key potential reasons based on real-world clinical practice | Abstract similar documents |
| A. N. Boyko, T. O. Simaniv, T. A. Prokopyeva, S. V. Petrov, M. V. Melnikov | ||
| "... agents are monoclonal antibodies (mAbs) targeting the CD20 receptor on lymphocytes: ocrelizumab ..." | ||
| Vol 13, No 6 (2021) | Meloxicam efficacy and safety in treatment of pain syndromes of different localization according to domestic studies | Abstract similar documents |
| O. A. Shavlovskaya, I. A. Bokova, N. I. Shavlovskiy | ||
| "... -модифицирующим действием. ..." | ||
| No 1S (2016): | Analysis of adult patients with epilepsy in the age continuum | Abstract similar documents |
| V. A. Karlov, O. S. Inozemtseva | ||
| "... указывают на возраст как самостоятельный фактор, модифицирующий качество жизни больных эпилепсией. ..." | ||
| Vol 13, No 5 (2021) | Treatment of cognitive impairment in arterial hypertension | Abstract similar documents |
| Yu. A. Starchina, K. S. Sleptcova | ||
| "... receptors (akatinol memantine) – in vascular CI. ..." | ||
| Vol 14, No 5 (2022) | Application of a new biological pathogenetic therapy of migraine in clinical practice: expert consensus of the Russian Headache Research Society | Abstract similar documents |
| A. V. Sergeev, G. R. Tabeeva, E. G. Filatova, A. V. Amelin, L. R. Akhmadeeva, E. R. Lebedeva, V. V. Osipova, Yu. E. Azimova, N. V. Latysheva, O. B. Doronina, K. V. Skorobogatykh | ||
| "... ) to the calcitonin gene related peptide (CGRP) ligand or receptor. These recommendations are based on current ..." | ||
| Vol 8, No 3 (2016) | Systematic analysis of basic and clinical studies of etifoxine | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova, V. A. Semenov, T. R. Grishina | ||
| "... . The anxiolytic effect of etifoxine is due, firstly, to the modulation of GABA receptor activity and, secondly ..." | ||
| Vol 5, No 4 (2013) | Dementia: epidemiology, clinical picture, diagnosis, approaches to therapy | Abstract similar documents |
| Irina Sergeyevna Preobrazhenskaya | ||
| "... to the pathogenetic therapy for dementia and the efficiency and safety of using NMDA receptor antagonists in patients ..." | ||
| Vol 5, No 1 (2013) | Blood pressure lowering-based prevention and the POWER trial | Abstract similar documents |
| Vladimir Anatolyevich Parfenov, S V Verbitskaya | ||
| "... results of the POWER trial evaluating the safety and efficacy of eprosartan, an angiotensin receptor ..." | ||
| Vol 5, No 2S (2013): Special issue "Stroke" | Management of patients with post-stroke dementia | Abstract similar documents |
| Svetlana Viktorovna Verbitskaya | ||
| "... the efficacy of central acetylcholinesterase inhibitors and the NMDA receptor antagonist akatinol memantine ..." | ||
| Vol 4, No 1 (2012) | Antyhypertensive therapy-based secondary prevention of ischemic stroke | Abstract similar documents |
| Vladimir Anatolyevich Parfenov, S V Verbitskaya, Yu A Starchina | ||
| "... ischemic attack. The possible neuroprotective effects of angiotensin II receptor blockers are discussed ..." | ||
| Vol 15, No 4 (2023) | Endocrine-inactive pituitary tumors: pathology and current approaches to diagnosis and treatment | Abstract similar documents |
| V. N. Nikolenko, B. A. Volel, A. N. Shkarubo, A. A. Nagajtseva, T. S. Zharikova, Yu. O. Zharikov | ||
| "... -inactive adenomas is based on the presence of receptors for somatostatin and dopamine in pituitary adenoma ..." | ||
| Vol 16, No 1 (2024) | Clinical case of an atypical course of autoimmune anti-NMDA encephalitis | Abstract similar documents |
| V. V. Goldobin, E. G. Klocheva, A. V. Dil, V. I. Golovkin, I. V. Chistova | ||
| "... Autoimmune encephalitis with antibodies against NMDA receptor (anti-NMDA encephalitis ..." | ||
| Vol 12, No 6 (2020) | Use of akatinol memantine for the treatment of Korsakoff's syndrome: a clinical case | Abstract similar documents |
| N. A. Tyuvina, T. N. Maksimova, S. V. Prokhorova, V. O. Vysokova | ||
| "... , the toxic effect of glutamate that is actively released through binding to NMDA receptors during the ethanol ..." | ||
| Vol 8, No 4 (2016) | NEUROTROPHIC EFFECTS OF ETIFOXINE | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova, V. A. Semenov, O. A. Limanova, I. V. Gogoleva | ||
| "... ; these are to relieve allodynia related to 3α-steroids and GABA receptors and to effectively treat cerebral edema ..." | ||
| Vol 13, No 4 (2021) | Neuroprotective therapy in acute ischemic stroke | Abstract similar documents |
| A. A. Kulesh | ||
| "... , natalizumab, interleukin 1 receptors antagonists, cerebrolysin, and other drugs have been analyzed. Non-drug ..." | ||
| Vol 14, No 4 (2022) | Piribedil in the treatment of mental and cognitive impairments in Parkinson's disease | Abstract similar documents |
| E. V. Yakovenko, F. A. Abbasov | ||
| "... of mental and cognitive impairments in PD, as well as the role of the dopamine receptor agonist piribedil ..." | ||
| Vol 12, No 1 (2020) | Drug-induced tardive dyskinesia | Abstract similar documents |
| T. M. Ostroumova, V. A. Tolmacheva, O. D. Ostroumova, V. A. Parfenov | ||
| "... of TD is associated with dopamine receptor blockade, gamma-aminobutyric acid depletion, cholinergic ..." | ||
| Vol 10, No 1 (2018) | Cranial dystonia | Abstract similar documents |
| V. A. Tolmacheva | ||
| "... and from the receptors within it. Botulinum toxin preparations show the highest efficacy in treating ..." | ||
| Vol 8, No 3 (2016) | Chemoreactome analysis of ethylmethylhydroxypyridine succinate | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, L. E. Fedotova, A. N. Gromov | ||
| "... of acetylcholine and GABA receptors, as well as that of cannabinoid receptor type 2. The anti-inflammatory effect ..." | ||
| Vol 16, No 5 (2024) | Experience of using Russian rizatriptan 10 mg tablets in routine clinical practice: results of a multicenter post-registration observational study “OPYT” | Abstract similar documents |
| G. R. Tabeeva, A. B. Danilov, M. I. Koreshkina, E. Z. Yakupov, A. V. Amelin, А. A. Artamonov | ||
| "... system, which led to the development and introduction of serotonin 5-HT1 receptor agonists (triptans ..." | ||
| Vol 16, No 4 (2024) | Aviandr is a new original drug for treating anxiety | Abstract similar documents |
| V. A. Parfenov | ||
| "... in AD is Aviandr, which blocks serotonergic 5-HT7, 5-HT2A, 5-HT2C and 5-HT6 receptors, adrenergic 2A, 2B ..." | ||
| Vol 14, No 2 (2022) | Post-COVID pain syndrome: a review of international observations | Abstract similar documents |
| O. A. Shavlovskaya, I. A. Bokova, N. I. Shavlovskiy | ||
| "... применять структурно-модифицирующие препараты замедленного действия – SYSADOA, среди которых предпочтение ..." | ||
| Vol 14, No 5 (2022) | Emotional disorders and their therapy in chronic low back pain | Abstract similar documents |
| A. I. Isaikin, T. I. Nasonova, A. Kh. Mukhametzyanova | ||
| "... on dopamine reuptake, interaction with sigma receptors, low incidence of side effects, and high adherence ..." | ||
| Vol 14, No 2 (2022) | Drug-induced tremor | Abstract similar documents |
| T. M. Ostroumova, V. A. Tolmacheva, O. D. Ostroumova | ||
| "... , lithium, tacrolimus and valproic acid. DIT mechanisms include dopamine receptors block, gamma-aminobutyric ..." | ||
| Vol 13, No 1 (2021) | Cognitive impairment in hypertension | Abstract similar documents |
| Yu. A. Starchina, V. V. Zakharov | ||
| "... of dementia. When dementia develops, reversible NMDA receptor inhibitors (memantine) and central ..." | ||
| Vol 11, No 1 (2019) | Molecular mechanisms of myoprotective action of chondroitin sulfate and glucosamine sulfate in sarcopenia | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, A. M. Lila, N. A. Shostak, K. V. Rudakov | ||
| "... with CD44 receptor, the CS/GS molecules inactivate the proinflammatory factor NF-kB, the activity of which ..." | ||
| Vol 8, No 2 (2016) | Effects of etifoxine: Chemoreactome simulation | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova, L. E. Fedotova, A. N. Gromov | ||
| "... neurotransmitter receptors; 2) anti-inflammatory activity; 3) the effect on hemodynamics and vascular walls; 4 ..." | ||
| Vol 10, No 1 (2018) | Vascular myelopathy: causes and mechanisms, possibilities of diagnosis and treatment | Abstract similar documents |
| G. V. Ponomarev, A. A. Skoromets, V. S. Krasnov, O. V. Rodionova, D. D. Glistenkova, N. F. Porkhun, S. A. Dambinova | ||
| "... stages. The investigation and introduction of specific biochemical markers (glutamate receptors ..." | ||
| 1 - 70 of 103 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
